These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38756760)

  • 1. Antifungal Treatment Duration in Hematology Patients With Invasive Mold Infections: A Real-life Update.
    Portillo V; Ragozzino S; Stavropoulou E; El-Khoury C; Bochud PY; Lamoth F; Khanna N; Neofytos D
    Open Forum Infect Dis; 2024 May; 11(5):ofae201. PubMed ID: 38756760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation.
    Glampedakis E; Roth R; Masouridi-Levrat S; Chalandon Y; Mamez AC; Giannotti F; Van Delden C; Neofytos D
    J Fungi (Basel); 2021 Sep; 7(10):. PubMed ID: 34682233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients?
    Roth RS; Masouridi-Levrat S; Giannotti F; Mamez AC; Morin S; van Delden C; Chalandon Y; Neofytos D
    Mycoses; 2022 Nov; 65(11):1061-1067. PubMed ID: 35815918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections.
    Roth RS; Masouridi-Levrat S; Giannotti F; Mamez AC; Glambedakis E; Lamoth F; Bochud PY; Erard V; Emonet S; Van Delden C; Kaiser L; Chalandon Y; Neofytos D
    Mycoses; 2022 Feb; 65(2):199-210. PubMed ID: 34936143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?
    Roth RS; Masouridi-Levrat S; Chalandon Y; Mamez AC; Giannotti F; Riat A; Fischer A; Poncet A; Glampedakis E; Van Delden C; Kaiser L; Neofytos D
    Open Forum Infect Dis; 2022 Jan; 9(1):ofab596. PubMed ID: 34993259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection.
    Ross JA; Lee B; Ma H; Tegtmeier B; Nanayakkara D; Dickter J; Spielberger R; Smith E; Pullarkat V; Forman SJ; Taplitz R; Nakamura R; Al Malki M; Dadwal SS
    Open Forum Infect Dis; 2024 Aug; 11(8):ofae409. PubMed ID: 39135965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation.
    Herity LB; Cruz OA; Aziz MT
    J Oncol Pharm Pract; 2022 Jun; 28(4):794-804. PubMed ID: 33906508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience.
    Neofytos D; Treadway S; Ostrander D; Alonso CD; Dierberg KL; Nussenblatt V; Durand CM; Thompson CB; Marr KA
    Transpl Infect Dis; 2013 Jun; 15(3):233-42. PubMed ID: 23432974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective, International Cohort Study of Invasive Mold Infections in Children.
    Wattier RL; Dvorak CC; Hoffman JA; Brozovich AA; Bin-Hussain I; Groll AH; Castagnola E; Knapp KM; Zaoutis TE; Gustafsson B; Sung L; Berman D; Halasa NB; Abzug MJ; Velegraki A; Sharma TS; Fisher BT; Steinbach WJ
    J Pediatric Infect Dis Soc; 2015 Dec; 4(4):313-22. PubMed ID: 26582870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
    Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
    Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
    Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study.
    Thompson GR; Garcia-Diaz J; Miceli MH; Nguyen MH; Ostrosky-Zeichner L; Young JH; Fisher CE; Clark NM; Greenberg RN; Spec A; Kovanda L; Croos-Dabrera R; Kontoyiannis DP
    Mycoses; 2022 Feb; 65(2):186-198. PubMed ID: 34888961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience.
    Kronig I; Masouridi-Levrat S; Chalandon Y; Glampedakis E; Vernaz N; Van Delden C; Neofytos D
    Mycopathologia; 2021 Dec; 186(6):775-788. PubMed ID: 34432216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field.
    Stafylidis C; Diamantopoulos P; Athanasoula E; Solomou E; Anastasopoulou A
    J Fungi (Basel); 2022 Oct; 8(11):. PubMed ID: 36354894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of antifungal treatment in mold infection: when is enough?
    Portillo V; Neofytos D
    Curr Opin Infect Dis; 2023 Dec; 36(6):443-449. PubMed ID: 37729658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient Characteristics and Risk Factors in Invasive Mold Infections: Comparison from a Systematic Review and Database Analysis.
    Sung AH; Martin S; Phan B; Benigno M; Stephens J; Chambers R; Aram JA
    Clinicoecon Outcomes Res; 2021; 13():593-602. PubMed ID: 34211287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy.
    Patel HP; Perissinotti AJ; Patel TS; Bixby DL; Marshall VD; Marini BL
    Open Forum Infect Dis; 2019 May; 6(5):ofz176. PubMed ID: 31123689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia.
    Le Clech L; Uguen M; Quinio D; Nevez G; Couturier MA; Ianotto JC; Berthou C; Guillerm G; Le Bars H; Payan C; Narbonne V; Baron R; Saliou P
    Curr Res Transl Med; 2020 Jan; 68(1):23-28. PubMed ID: 31787568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study.
    Fracchiolla NS; Sciumè M; Orofino N; Guidotti F; Grancini A; Cavalca F; Freyrie A; Goldaniga MC; Consonni D; Mattiello V; Pettine L; Cortelezzi A
    PLoS One; 2019; 14(5):e0216715. PubMed ID: 31071175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive mold infections in acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Chien SH; Liu YC; Liu CJ; Ko PS; Wang HY; Hsiao LT; Chiou TJ; Liu JH; Gau JP
    J Microbiol Immunol Infect; 2019 Dec; 52(6):973-982. PubMed ID: 30322746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.